Balanced news tone
News Sentiment
MRNA sentiment intelligence
Moderna Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
80/100 classification confidence.
directly relevant articles
high-authority source matches
-14.4% over one week, +36.8% over four weeks, trend active, and near fair-value range.
Moderna (MRNA) Stock Looks Stretched On Sales But Reasonable On Momentum
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Moderna's Revenues See Strong International Momentum in Q1 Earnings
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 12 May 2026 07:00
- Source
- TradingView
Moderna shares jump 8% after U.S. national tests positive for hantavirus
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Investing.com
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Has The Market Rerated Moderna (MRNA) Too Quickly After Its Recent Share Price Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- simplywall.st
Moderna (MRNA) Loss Of US$2.8b Keeps Bearish Narratives In Focus
- Tone
- Negative 18/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- simplywall.st
MRNA Stock Rises Pre-Market: Moderna Bets On US Comeback With Flu Vaccine Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- Stocktwits
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Apr 2026 07:00
- Source
- StockStory
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine Companies
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Feb 2026 08:00
- Source
- Genetic Engineering and Biotechnology News
US FDA reverses course, will review Moderna's flu vaccine application
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2026 08:00
- Source
- Reuters
US FDA declines Moderna flu vaccine review amid vaccine guidance rollback
- Tone
- Negative 34/100
- Event
- Guidance
- Published
- 11 Feb 2026 08:00
- Source
- Al Jazeera